Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
M
MacKay, J. Andrew
University of Southern California
(
W1230-01-03
)
Elastin-Like Polypeptide (ELP) Antibody Fusions Targeting IL-6: Pharmacology and Pharmacokinetics
J. Andrew MacKay
Favorite
Maijorovaite, Zaneta
Teva Pharmaceuticals, Inc.
(
W1230-01-02
)
Impact of Amino Acids as Excipients in Biologic Drug Products Formulation Development
Zaneta Maijorovaite
Favorite
Manandhar, Pragya
Teva Pharmaceuticals, Inc.
(
W1230-01-02
)
Impact of Amino Acids as Excipients in Biologic Drug Products Formulation Development
Pragya Manandhar
Favorite
Mangadu, Ruban
Merck & Co., Inc.
(
T1230-02-08
)
Quantitation of Soluble Tumor-Associated Antigens (sTAA) in Tumor Interstitial Fluid (TIF) Isolated from Frozen Solid Tumors
Ruban Mangadu
Favorite
Manikkath, Jyothsna
Manipal Academy of Higher Education
(
T1230-01-04
)
Iontophoretic Transdermal Delivery of a Bioactive Molecule: Comparison of Nanoliposomal Platforms with Passive Delivery
Jyothsna Manikkath
Favorite
Mao, Yan
Boehringer-Ingelheim
(
T1230-02-07
)
A Validated Immunocapture LC-MS/MS Hybrid Assay for the Quantitation of a Novel Multi-Domain Therapeutic Protein in Human Plasma with Clinical Sample Analysis
Yan Mao
Favorite
Marchand, Mathilde
Certara
(
T1230-02-09
)
Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Mathilde Marchand
Favorite
Marchando, Sydney
Phosphorex
(
W1330-02-09
)
Using Cryo-TEM to Characterize Structural Details of LNPs during Manufacturing
Sydney Marchando
Favorite
Martin, William
EpiVax, Inc.
(
T1130-02-11
)
Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods
William Martin
Favorite
(
W1130-02-09
)
Immunogenicity Risk Assessment of Salmon Calcitonin Peptide Impurities Using In Silico and In Vitro Methods
William Martin
Favorite
(
W1230-02-11
)
Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics and Vaccines Using In Silico and In Vitro Methods
William Martin
Favorite
(
W1530-02-10
)
An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)
William Martin
Favorite
Mattei, Aimee
EpiVax, Inc.
(
T1130-02-11
)
Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods
Aimee Mattei
Favorite
(
W1130-02-09
)
Immunogenicity Risk Assessment of Salmon Calcitonin Peptide Impurities Using In Silico and In Vitro Methods
Aimee Mattei
Favorite
(
W1530-02-10
)
An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)
Aimee Mattei
Favorite
McAllister, Mitchell
EpiVax, Inc.
(
W1230-02-11
)
Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics and Vaccines Using In Silico and In Vitro Methods
Mitchell McAllister
Favorite
McNeil, Mary
NeuroOne
(
W1430-01-04
)
Innovative Device for Concomitant Therapeutic Compound Delivery into the Brain and Neural Recordings - Feasibility Bench and In Vivo Studies
Mary McNeil
Favorite
Meissen, John K.
AstraZeneca
(
W1230-02-09
)
LC-MS FFPE Tissue Analysis Across Multiple Murine Tissues Supports Mouse Relevance for On-Target/Off-Tumor Toxicity Assessment for Anti-STEAP2 CAR-T Therapeutic Development
John K. Meissen
Favorite
Mejia Cardenas, Karina
BioAgilytix Labs
(
W1530-02-09
)
Development of Non-Cell Based Potency Assays for Bispecific Antibodies
Karina Mejia Cardenas
Favorite
Mekhssian, Kevork
Altasciences
(
T1230-02-11
)
Sensitive Quantitation of Antisense Oligonucleotides Using Capitainer
®
qDBS Microsampling Device Coupled with Hybridization LC-MS/MS
Kevork Mekhssian
Favorite
Melendez, Rachel
Genentech, Inc.
(
T1330-02-06
)
Utilizing a Bead-Based Sample Pretreatment to Overcome Drug Interference in Developing a Ligand Binding Neutralizing Antibody Assay
Rachel Melendez
Favorite
(
T1530-02-08
)
Cross Validation of Pharmacokinetic Assays: Experimental and Statistical Design
Rachel Melendez
Favorite
Meng, Shuxia
Genentech, Inc.
(
T1330-02-07
)
Optimizing and Validating an In Vitro Transcytosis Assay for Predicting Pharmacokinetics in Drug Discovery and Process Development
Shuxia Meng
Favorite
Menon, Sreejit
Croda, Inc.
(
T1330-01-05
)
Optimizing Lipid Nanoparticles (LNPs) Processing for siRNA Delivery by Microfluidics System
Sreejit Menon
Favorite
Milewski, Mikolaj
Merck & Co., Inc.
(
T1230-01-01
)
Parallel-Competitive Absorption Metabolism Model for Calculation of Subcutaneous Bioavailability of Monoclonal Antibodies
Mikolaj Milewski
Favorite
Misra, Bishal
West Virginia University
(
T1030-01-05
)
Flash Nanoprecipitation Permits Self-assembly of Ionizable Lipid Nanoparticles for Nucleic Acid Delivery
Bishal Misra
Favorite
(
T1430-01-04
)
Ionizable Lipid Nanoparticles for Dual siRNA/Chemotherapy Delivery for B-cell ALL Treatment
Bishal Misra
Favorite
Mittal, Bhagwant
Post Graduate Institute of Medical Education and Research
(
W1530-02-08
)
Non-invasive Molecular Imaging of V3 Receptors to Localize ACTH-Dependent Cushing's Syndrome and Precision Surgery of Corticotropinoma
Bhagwant Mittal
Favorite
Miura, Kanako
Daiichi Sankyo Co., Ltd.
(
T1030-01-01
)
Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides
Kanako Miura
Favorite
(
W1230-01-01
)
Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides IV Evaluation of Compactness of Oligonucleotides for Determining Their Higher-Order Structure
Kanako Miura
Favorite
Miyahara, Yuya
Mitsubishi Tanabe Pharma Corporation
(
T1230-02-06
)
Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Overview
Yuya Miyahara
Favorite
(
T1430-02-06
)
Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) C-terminal Lys Clipping
Yuya Miyahara
Favorite
(
W1130-02-06
)
Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (2) Oxidation
Yuya Miyahara
Favorite
(
W1330-02-06
)
Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) Deamidation
Yuya Miyahara
Favorite
Miyajima, Makoto
Daiichi Sankyo Co., Ltd.
(
W1230-01-01
)
Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides IV Evaluation of Compactness of Oligonucleotides for Determining Their Higher-Order Structure
Makoto Miyajima
Favorite
Miyashita-Lin, Emily
Cellentia, Inc.
(
W1430-02-08
)
In Vitro Method Using Circulating Tumor Cells-Derived Organoids from Patients with Solid Tumors to Transform Oncology Drug Development
Emily Miyashita-Lin
Favorite
Mizoguchi, Junichi
Eisai Co., Ltd.
(
T1330-01-01
)
Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides II Circular Dichroism Spectroscopy and Nuclear Magnetic Resonance Analysis for Determining Higher-Order Structure
Junichi Mizoguchi
Favorite
Moinuddin, Sakib Mohammad
California Northstate University
(
W1030-01-04
)
Preparation and Scale-Up of Liposomal Amphotericin B Formulation and a Comparison with Commercially Available Counterpart, Ambisome®
Sakib Mohammad Moinuddin
Favorite
Moreno, Jonathan
Chapman University
(
W1030-02-09
)
Design and Evaluation of a Cyclic Peptide-Epirubicin Conjugate to Enhance Anticancer Activity and Reduce Cardiac Toxicity
Jonathan Moreno
Favorite
Mosharraf, Mitra
Engimata
(
T1330-01-04
)
Predicting the Aggregation Behavior of Liposomes Using Thermal Analysis
Mitra Mosharraf
Favorite
(
W1430-01-05
)
Characterization of Protein Antigens in Liposomal Vaccines Using Differential Scanning Fluorimetry
Mitra Mosharraf
Favorite
Murai, Aliaa
Qatar University
(
W1330-01-04
)
Prolonged Ocular Delivery of Sunitinib from Poly (diol-tricarballylate) Injectable Biodegradable Elastomeric Tiny Implant for Diabetic Retinopathy Treatment
Aliaa Murai
Favorite
Murashov, Mikhail
Merck & Co., Inc.
(
T1230-01-01
)
Parallel-Competitive Absorption Metabolism Model for Calculation of Subcutaneous Bioavailability of Monoclonal Antibodies
Mikhail Murashov
Favorite
Mutalik, Srinivas
Manipal College of Pharmaceutical Sciences
(
T1230-01-04
)
Iontophoretic Transdermal Delivery of a Bioactive Molecule: Comparison of Nanoliposomal Platforms with Passive Delivery
Srinivas Mutalik
Favorite
